ALEC:NSD-Alector, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.21

Change

-1.23 (-7.05)%

Market Cap

USD 1.38B

Volume

0.66M

Average Target Price

USD 32.67 (+101.52%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.94 (+0.82%)

USD61.55B 23.20 18.26
REGN Regeneron Pharmaceuticals, Inc

-6.79 (-1.25%)

USD57.86B 19.87 14.64
MRNA Moderna, Inc

+7.84 (+6.26%)

USD49.52B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+0.12 (+0.08%)

USD34.50B 36.61 33.83
SGEN Seagen Inc

-5.02 (-2.63%)

USD34.15B 72.05 70.76
BGNE BeiGene, Ltd

-5.81 (-1.60%)

USD33.65B N/A N/A
RPRX Royalty Pharma plc

+0.07 (+0.14%)

USD31.48B 22.60 11.90
GMAB Genmab A/S

-0.19 (-0.44%)

USD28.72B 26.59 3.08
BNTX BioNTech SE

+2.20 (+2.13%)

USD25.21B -99,999.99 N/A
INCY Incyte Corporation

-2.47 (-2.56%)

USD21.10B 47.64 35.20

ETFs Containing ALEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.14% 38% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.14% 38% F 54% F
Trailing 12 Months  
Capital Gain -30.35% 19% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.35% 19% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.31% 44% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.31% 44% F 44% F
Risk Return Profile  
Volatility (Standard Deviation) 26.20% 89% B+ 56% F
Risk Adjusted Return 12.65% 46% F 41% F
Market Capitalization 1.38B 77% C+ 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.31 56% F 37% F
Price / Cash Flow Ratio -13.92 66% D 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -63.76% 51% F 18% F
Return on Invested Capital -235.05% 7% F 3% F
Return on Assets -22.11% 61% D- 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 10.56 11% F 7% F
Short Percent 15.27% 16% F 13% F
Beta 1.99 28% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector